Printer Friendly

CANTAB'S DISC VIRUS TECHNOLOGY SHOWS EFFICACY AGAINST HERPES

 CANTAB'S DISC VIRUS TECHNOLOGY SHOWS EFFICACY AGAINST HERPES
 CAMBRIDGE, England, Sept. 2 /PRNewswire/ -- Researchers at Cantab Pharmaceuticals (NASDAQ: CNTBY) and Cambridge University have reported results of successful collaborative experiments on a genetically altered vaccine against the herpes simplex virus. The findings, presented at the 17th International Herpesvirus Workshop in Edinburgh, show that Cantab's proprietary DISC technology is highly effective in preventing the development of HSV-1 disease in mice.
 Cantab's DISC (Disabled Infectious Single Cycle) technology is used to produce genetically modified viruses. A DISC virus will stimulate a full immune response equivalent to a whole virus, but will not replicate or spread infection. A prototype DISC HSV-1 vaccine proved a hundred times more effective in preventing development of HSV-1 disease in the mouse model when compared with a conventional killed vaccine formulation. The desired immune response was produced at very low dosages, but the DISC virus preparation did not display any pathogenic effects even when administered at relatively high doses.
 "The results of these studies underline the advantages of the DISC vaccination strategy," said Paul Haycock, M.D., president and chief executive officer of Cantab, "and should allow us to induce a full spectrum of immune response to a number of viral antigens in a safe and effective manner."
 HSV-1 is closely related to HSV-2, the virus causing genital herpes, which currently affects more than 10 million people in the United States and Europe. Cantab is developing a DISC product for use as a therapeutic antigen for the treatment of genital herpes.
 Cantab is engaged in the research and development of biopharmaceuticals that use the highly selective properties of the immune system to treat disease. The company has research and development programs in two principle areas: Leucocyte Modulators, which regulate or block immune system function, and Therapeutic Antigens, which activate specific immune responses. Cantab's initial therapeutic focus includes research programs in the prevention of organ transplant rejection, and the treatment of Crohn's disease and cervical cancer, as well as work on genital herpes. The company has established collaborations with Baxter Healthcare Corporation, Cambridge University and with researchers at several other British academic institutions.
 -0- 9/2/92
 /CONTACT: Paul Haycock, M.D. of Cantab Pharmaceuticals, in the United Kingdom 011-44-223-423413, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, 212-979-9180, for Cantab Pharmaceuticals/
 (CNTBY) CO: Cantab Pharmaceuticals ST: Cambridge IN: MTC SU:


LD-TM -- NY004 -- 5749 09/02/92 08:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 2, 1992
Words:402
Previous Article:NEWBRIDGE FRAME RELAY PRODUCTS UNDERGOING FIELD TRIALS WITH AGT, CALGARY DISTRICT HOSPITAL GROUP AND UNGERMANN-BASS
Next Article:GRANITE DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
CANTAB, BAXTER SUCCESSFULLY COMPLETE PHASE I/II TRIALS FOR DRUG THAT REDUCES REJECTION IN ORGAN TRANSPLANTS
CANTAB DEMONSTRATES POTENTIAL OF DISC VIRUS VACCINE FOR PREVENTION AND TREATMENT OF GENITAL HERPES
STUDY SHOWS NEW HERPES VACCINE IS SAFE AND PROVIDES GOOD IMMUNE RESPONSE
Novel Vaccine for the Management of Herpes Simplex Infection Licensed to Glaxo Wellcome by Cantab
Robertson Stephens Initiates Coverage on Cantab Pharmaceuticals
CEL-SCI Corporation's Herpes Simplex Vaccine Protects Mice Against Herpes Infection
CEL-SCI's Herpes Vaccine Shows Protection Against Herpes Infection in Animals
New Herpes Vaccine Similar to One for AIDS.
AVANT Awarded Grant for Herpes Vaccine Development.
Herpes vaccine progresses. (Immunology).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters